Stocks and Investing
Stocks and Investing
Thu, December 15, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrea Tan Initiated (VERV) at Strong Sell and Held Target at $13 on, Dec 15th, 2022
Andrea Tan of Goldman Sachs, Initiated "Verve Therapeutics, Inc." (VERV) at Strong Sell and Held Target at $13 on, Dec 15th, 2022.
Andrea has made no other calls on VERV in the last 4 months.
There are 3 other peers that have a rating on VERV. Out of the 3 peers that are also analyzing VERV, 1 agrees with Andrea's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Initiated at Hold and Held Target at $48 on, Thursday, October 6th, 2022
These are the ratings of the 2 analyists that currently disagree with Andrea
- Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $35 on, Tuesday, November 8th, 2022
- Dae Gon Ha of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $56 on, Thursday, August 25th, 2022
Contributing Sources